MRD response-driven phase I/II study for newly diagnosed multiple myeloma patients using higher doses of twice-weekly carfilzomib (45 and 56 mg/m2) in combination with lenalidomide and dexamethasone Meeting Abstract


Authors: Korde, N.; Mailankody, S.; Smith, E. L.; Lendvai, N.; Hassoun, H.; Lesokhin, A.; Hultcrantz, M.; Chung, D. J.; Shah, G. L.; Koehne, G.; Landau, H.; Roshal, M.; Dogan, A.; Giralt, S. A.; Mastey, D.; Evancha, N.; Devlin, S. M.; Landgren, O.
Abstract Title: MRD response-driven phase I/II study for newly diagnosed multiple myeloma patients using higher doses of twice-weekly carfilzomib (45 and 56 mg/m2) in combination with lenalidomide and dexamethasone
Meeting Title: 59th Annual Meeting of the American Society of Hematology (ASH)
Journal Title: Blood
Volume: 130
Issue: Suppl. 1
Meeting Dates: 2017 Dec 9-12
Meeting Location: Atlanta, GA
ISSN: 0006-4971
Publisher: American Society of Hematology  
Date Published: 2017-12-07
Language: English
ACCESSION: WOS:000432419700333
PROVIDER: wos
Notes: Meeting Abstract: 3133 -- Source: Wos
MSK Authors
  1. Sergio Andres Giralt
    500 Giralt
  2. Hani Hassoun
    143 Hassoun
  3. Guenther Koehne
    174 Koehne
  4. Heather Jolie Landau
    173 Landau
  5. Nikoletta Lendvai
    78 Lendvai
  6. Alexander Meyer Lesokhin
    106 Lesokhin
  7. David Chung
    75 Chung
  8. Sean McCarthy Devlin
    277 Devlin
  9. Eric Smith
    26 Smith
  10. Ahmet Dogan
    162 Dogan
  11. Mikhail Roshal
    58 Roshal
  12. Carl Ola Landgren
    175 Landgren
  13. Neha Sanat Korde
    56 Korde
  14. Gunjan Lalitchandra Shah
    67 Shah
  15. Donna Mastey
    1 Mastey